At present, only a few drugs have been approved by the FDA for therapy of viral infections in humans. There is a great need for antiviral drugs with increased potency and decreased toxicity, as well as drugs to treat viral diseases for which no drug or vaccine is currently available. Two approaches for development of antiviral drugs are described-an empirical strategy and a rational strategy-with several examples of each.
INTRODUCTION
Many compounds have potent antiviral activity in cell culture, but only about 1 percent of these compounds that have antiviral activity in cell culture are also active in animal systems. Of those that have good antiviral activity and acceptable toxicity in animals, only a few become antiviral drugs for use in humans. Seven synthetic compounds ( Fig. 1 ) and alpha interferon have been approved by the FDA as antiviral agents. The specific viral infections for their use as well as the molecular basis for their antiviral activity have been well reviewed [1] [2] [3] [4] [5] [6] [7] [8] [9] (Table 1) . Four of these compounds are for the therapy of infections caused by members of the herpesvirus family. The clinically approved antiherpetic drugs include: 5-iodo-2'-deoxyuridine (idoxuridine; IUdR; IdUrd); 5-trifluoromethyl-2'-deoxyuridine (trifluridine; F3TdR;F3dThd;TFT); 9-f-D-arabinofuranosyl adenine (vidarabine; ara-A); and 9-(2-hydroxyethoxymethyl)guanine (acyclovir; ACV). A fifth compound, amantadine (1-aminoadamantane; 1-adamantanamine HCI), is approved for the therapy and prophylaxis of respiratory infections caused by the influenza A virus. A sixth antiviral agent, ribavirin (1-,B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; virazole), is approved for therapy of severe respiratory infections in infants and children caused by the respiratory syncytial virus. The seventh antiviral agent, 3'-azido-3'-deoxythymidine (AZT; zidovudine), has None of these FDA-approved drugs, however, is without toxicities [9, 10] (Table 2 ) and hence there is a strong need for improved drugs not only to improve efficiency but also to circumvent these problems of toxicity. There is also a need to find an effective therapy of viral infections for which we do not at present have clinically useful drugs or vaccines [11] .
Among the human viruses or the diseases they produce for which we need useful or improved drugs or vaccines, we may list the following: HIV-1 (AIDS), cytomegalovirus, Epstein-Barr virus, HSV-1, HSV-2, varicella virus, influenza A, influenza B, enterovirus, hepatitis A, hepatitis B, adenovirus, common cold, bronchiolitis, croup, dengue, poliomyelitis, measles, rabies, warts, chickenpox, mumps, and rubella. DISCUSSION A variety of approaches have been pursued for the development of antiviral drugs, as well as drugs in general, and these may be broadly classified as either the rational or the empirical strategy [12] [13] [14] [15] [16] .
The empirical approach involves repeated structure modification of a lead compound until optimal antiviral activity is obtained, but with an acceptable therapeutic index. The probability of producing such a compound can be improved by combining structure-activity relationships with computer-graphic model building. This empirical approach perhaps could be termed also the "rational serendipity" approach, because structural modifications made are based on a rational extension of existing knowledge with other or similar compounds. A simple structural modification may not, however, produce the desired end product because any modification of structure will produce changes in size, shape, electronic distribution, partition coefficient, solubility, pKa, chemical reactivity, metabolism, and hydrogen-bonding capabilities [16] . The hope is that the change being made will result in improved potency, selectivity, duration of action, bioavailability, and reduced toxicity [16] . If the hope is realized, the achievement may be termed "rational serendipity."
An example of a "rational serendipity" approach for development of drugs is that developed by Hitchings and his colleagues [ 17, 18] . They were the first to study analogs of purines and pyrimidine bases as potential inhibitors of nucleic acid biosynthesis. The importance of nucleic acids for cellular replication had already been established. Their approach then was systematically to examine the effect of structural changes on the potency of a compound as an inhibitor of bacterial replication. Analogs of purines, pyrimidines, nucleosides, and nucleotides have since been of value in the elucidation of metabolic pathways as well as in the therapy of cancer, metabolic disorders, and therapy of various infectious agents.
Another example of the empirical or "rational serendipity" approach is the modification of the thymidine component of DNA, by replacement of the methyl group on carbon-5 of the pyrimidine moiety with an iodine atom (Fig. 2) . Rationale dictated that since the van der Waals' radii of the methyl group and the iodine atom were very similar, 2.OOA and 2.1 5A, respectively, steric hindrance would not be a problem. The serendipity entered in when 5-iodo-2'-deoxyuridine (idoxuridine, IDU, IdUrd, IUdR), originally designed to be an anticancer drug, instead became the first antiviral compound to be approved by the FDA for therapy of a viral infection-herpetic keratitis.
There are many examples of structure modification which resulted in the formation of compounds with antiviral activity. are arranged, when combined with molecular modeling and interactive computer graphics, affords the design of specific drugs [13] [14] [15] [16] . This approach may also allow us to understand how a known antiviral drug exerts its effect. For example, the rhinovirus was crystallized and allowed to interact with a Sterling-Winthrop compound which is known to prevent viral uncoating, and then the complex was subjected to X-ray crystallography. Analysis afforded a computergraphic picture of how the drug binds into a hydrophobic pocket beneath the canyon floor of the rhinovirus (Fig. 4) . Tihis interaction produced a large conformational change in 3-stretches of the VP-I polypeptide chain, which increased the rigidity of the capsid proteins, with resultant inhibition of the disassembly of the virus [19] [20] [21] [22] [23] [24] . Such knowledge allows the more intelligent modification of structure and also allows us to understand on an atomic level why these drugs are effective or ineffective.
An exciting approach for rational drug design is based on our understanding of gene structure and function [25] [26] [27] . Some success has already been achieved in the synthesis of "anti-sense" oligodeoxyribonucleotides, whose base pairs are complementary to critical regions of the viral genome or mRNA and, following specific hybridization, block viral expression [28] [29] [30] [31] (Fig. 5) . Thus, selective inhibition of gene expression is achieved. There are, however, several problems in the use of anti-sense oligonucleotides: (1) tached to anti-sense oligomer [35] .
possible limited accessibility of the target nucleic acid sequence because of the tight binding proteins. Some of these problems have been approached in several laboratories and will be briefly described. The phosphodiester linkage, for example, has been converted into non-ionic phosphotriesters, alkylphosphonates [32] , and phosphorothioates [33] , as well as nonphosphorous moieties such as amides, carbonates, carbamate, and siloxane [34] . The consequence of such conversion is a decreased sensitivity to enzymic degradation as well as improved transport into the cell because of increased lipophilicity (decreased 3* 5.
FIG. 7 . DNA triple-stranded formation of an oligodeoxyribonucleotide with attached cleaving moiety (EDTA-Fe) to double-stranded DNA [37] . polarity). Unfortunately, the alkylphosphonates introduce an undesirable chiral phosphorus which complicates synthesis.
An increased stability of hybrid formation was achieved by the conjugation of an intercalating compound such as an acridine derivative to either the 3'-or the 5'-terminal of the oligomer via a pentamethylene tether. The intercalating acridine provides additional binding energy to stabilize the hybrid complex and also decreases susceptibility to endonuclease degradation [35] (Fig. 6) .
Transport of the oligodeoxyribonucleotide was markedly increased by covalently linking cytidine to the 3'-terminus, oxidatively cleaving the 2', 3'-bond of cytidine, and by subsequent reaction with the epsilon amino moiety of poly-L-lysine forming an N-morpholino ring linking the oligomer to poly-L-lysine [36] .
A potentially very important approach is termed "affinity cleaving." This technique involves the use of a complementary oligomer to carry a reactive moiety, which can, under appropriate conditions, destroy a specific portion of the nucleic acid genome. The oligomer-conjugate can react with double-stranded DNA at a specific DNA sequence, forming a triple helix, and a cleaving function, such as EDTA chelated to Fe'+, under appropriate redox conditions can generate highly reactive hydroxyl radicals from oxygen, which react and destroy the deoxyribose moieties. Where the deoxyribose moiety is cleaved on both strands of DNA, the gene is destroyed [37] [38] [39] ( Fig. 7) .
This method is truly a rational chemotherapeutic approach for inactivation of specific genes. One can visualize destruction of any viral gene which is integrated into cellular DNA. At present, the replicating virus but not the latent virus is susceptible to inhibition by our present armamentarium of antiviral drugs. Can this technique destroy the AIDS virus when it is integrated into cellular DNA as proviral DNA? Can this approach destroy the latent herpesvirus responsible for recurrences of genital herpes, or the varicella-zoster virus responsible for shingles, or, for that matter, an oncogene if involved in the progression of cancer?
In summary, it appears that some exciting new approaches for the design of antiviral agents are being pursued. We are, however, in the very early stages of development, and there are many obstacles which must be overcome before the "rationalserendipity" approach, or even what we optimistically term the "rational" approach, becomes a truly rational approach.
